Last reviewed · How we verify
quetiapine fumarate or valproate
This is a combination of two distinct psychiatric medications: quetiapine fumarate (an atypical antipsychotic) and valproate (a mood stabilizer), each working through different neurochemical pathways.
This is a combination of two distinct psychiatric medications: quetiapine fumarate (an atypical antipsychotic) and valproate (a mood stabilizer), each working through different neurochemical pathways. Used for Bipolar disorder (acute mania or mixed episodes), Schizophrenia, Major depressive disorder with psychotic features.
At a glance
| Generic name | quetiapine fumarate or valproate |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic + anticonvulsant mood stabilizer combination |
| Target | Dopamine receptors (D2), serotonin receptors (5-HT1A, 5-HT2A); GABA pathway, histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Quetiapine fumarate antagonizes dopamine and serotonin receptors, reducing psychotic symptoms and stabilizing mood. Valproate increases GABA levels and modulates histone deacetylase activity, providing mood stabilization and anticonvulsant effects. The combination targets both psychotic and mood symptoms in psychiatric disorders.
Approved indications
- Bipolar disorder (acute mania or mixed episodes)
- Schizophrenia
- Major depressive disorder with psychotic features
Common side effects
- Sedation/somnolence
- Weight gain
- Dizziness
- Tremor
- Nausea
- Headache
- Hepatotoxicity (valproate)
- Pancreatitis (valproate)
Key clinical trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium (PHASE4)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Sequential Multiple Assignment Treatment for Bipolar Disorder (PHASE4)
- Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes (PHASE4)
- Treatment of Mania Symptoms With Drug Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- quetiapine fumarate or valproate CI brief — competitive landscape report
- quetiapine fumarate or valproate updates RSS · CI watch RSS
- AstraZeneca portfolio CI